Investment Overview >$8bn. | Leverage ratio stable with 2023 year-end | --- | --- | --- | --- | --- | |---------------------------|----------|----------|----------|----------| | $ mil | Dec 2021 | Dec 2022 | Dec 2023 | Mar 2024 | | Cash and cash equivalents | 737 | 706 | 693 | 575 | | Gross Debt (1) | 9,134 | 8,913 | 8,760 | 8,714 | | Net Debt (1) | 8,397 | 8,207 | 8,067 | 8,139 | Furthermore, Organon's Established Brands division consists of >50 drugs whose patents are expiring, or have long since expired, ...